ERBB2 and triple-negative breast carcinoma: This study focused on four clinical areas representing differing levels of maturity of the PM landscape: HER2+ metastatic breast cancer (mBC), HR+/HER2− mBC, HR−/HER2- mBC [also known as triple-negative breast cancer (TNBC)], and mNSCLC.